NASDAQ · Medical - Instruments & Supplies

Anbio Biotechnology (NNNN) Stock

$4.62 -5.71% NASDAQ: NNNN Healthcare

Valuation

MetricValue
Price$4.62
Market Cap$202.78M
P/E Ratio32.57
P/B Ratio9.17
P/S Ratio23.48
EPS (TTM)$0.15
52-Week High$51.33
52-Week Low$4.56
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE27.49%
ROA28.07%
ROCE25.46%
Gross Margin87.06%
Operating Margin66.47%
Net Margin72.09%
Debt/Equity0.00
Current Ratio344.31

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$24.0M$7.0M$8.0M$9.0M
Operating Profit$2.0M$10.0M$2.0M$2.0M$6.0M
Net Profit$3.0M$10.0M$2.0M$2.0M$6.0M
EPS$0.03$0.07$0.01$0.06$0.16
Op Margin55.5%43.3%29.2%24.4%66.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$5.0M$14.0M$16.0M$19.0M$30.0M
Total Liabilities$2.0M$1.0M$1.0M$2.0M$0
Cash$4.0M$7.0M$10.0M$12.0M$8.0M
Borrowings$0$0$0$0$0

Latest News

Anbio Biotechnology Files Mixed Shelf Registration MT Newswires · Jul 9, 2026 US Undiscovered Gems To Watch In May 2026 Simply Wall St. · May 29, 2026 Discover 3 Undiscovered Gems in the US Market Simply Wall St. · May 29, 2026 Uncovering US Market's 3 Undiscovered Gems With Potential Simply Wall St. · May 28, 2026 Discovering US Undiscovered Gems In May 2026 Simply Wall St. · May 21, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$4.0M$4.0M$1.0M$2.0M$-7.0M
Investing Cash Flow$0$-2.0M$2.0M$0$-4.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$4.0M$3.0M$3.0M$2.0M$-4.0M
Free Cash Flow$4.0M$4.0M$1.0M$2.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.33
EV / EBITDA41.49
FCF Yield0.00%
Quick Ratio344.31
Interest Coverage0.00
Return 1Y-77.97%
Return 3Y—
Return 5Y—

Ownership

Insiders Held4.78%
Institutions Held4.90%
Institutions Float Held5.15%
Institutional HolderSharesReport Date
Geode Capital Management, LLC25,7632026-03-31
BNP Paribas Financial Markets10,4002026-03-31
Morgan Stanley7,3382026-03-31
UBS Group AG6,3392026-03-31
Blue Trust, Inc.52026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $340.42 +1.11% 38.93 $5.00T 0.32%
MSFTMicrosoft Corporation $522.61 -1.35% 28.68 $3.88T 0.76%
GOOGLAlphabet Inc. $348.29 -0.63% 16.94 $4.22T 0.26%
AMZNAmazon.com, Inc. $254.06 -2.25% 19.82 $2.73T 0.00%
METAMeta Platforms, Inc. $720.89 -0.06% 27.93 $1.84T 0.28%

About Anbio Biotechnology

Anbio Biotechnology is led by CEO Michael Lau, employs 27 people, headquartered in DE, publicly traded since 2025.

Anbio Biotechnology (NNNN) stock trades at $4.62 with a market capitalization of $202.78M. The stock is valued at a price-to-earnings (P/E) ratio of 32.57, price-to-book of 9.17, price-to-sales of 23.48. Over the past 52 weeks the stock has ranged between $4.56 and $51.33, and currently trades 91.0% below its 52-week high.

On profitability, Anbio Biotechnology generates a return on equity (ROE) of 27.49% — well above the market average, a sign of a high-quality business, return on capital employed of 25.46%, an operating margin of 66.47%, a net profit margin of 72.09%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides